Hims & Hers Health (NYSE:HIMS) stock fell 4.1% in after-hours trading on Thursday following a Bloomberg report that revealed ...

Hims & Hers first told investors about a regulatory review in July 2024, but Bloomberg's report adds new color on what ...

Hims & Hers shares fall after a report says the FTC has investigated its cancellation policies and billing practices for over ...

The U.S. Federal Trade Commission is probing complaints about telehealth platform Hims & Hers regarding its advertising and ...

For more than a year, the Federal Trade Commission has been investigating Hims & Hers Health Inc.’s business practices, including whether it has made it too hard for customers to cancel subscriptions, ...

After Bloomberg reported, citing people familiar with the probe, that the Federal Trade Commission has been investigating ...

Investing.com -- Hims & Hers Health (NYSE:HIMS) stock dropped 2.6% on Friday following reports that the Federal Trade Commission has been investigating the telehealth company's business practices for ...

Truist lowered the firm’s price target on Hims & Hers to $37 from $48 and keeps a Hold rating on the shares. The firm’s intra-quarter Truist Card Data suggests that the company’s GLP-1 related ...

Recent health-related developments include Britain's decisions on the bioethanol industry, Berkshire Hathaway's new stake in ...

Berkshire Hathaway invests in UnitedHealth; FTC investigates Hims & Hers for advertising practices; U.S. health department ...